百家乐怎么玩-澳门百家乐官网娱乐城网址_网上百家乐是不是真的_全讯网888 (中国)·官方网站

Recent advances in the synthesis, stability, and activation of platinum(IV) anticancer prodrugs
20210518_1.jpeg

Published on Angewandte Chemie (18 May 2021)

 

Author(s): Zoufeng Xu, Zhigang Wang, Zhiqin Deng, Guangyu Zhu*

 

Abstract

Platinum-based anticancer drugs have been widely applied in clinical settings for more than 40 years. The remarkable breakthroughs that have come from the use of these complexes in cancer therapy have stimulated a continual search for new platinum anticancer drugs. The most promising result of these efforts is a prodrug strategy based on the use of platinum(IV) versions of the traditional platinum(II) anticancer drugs. Hence, the design of synthetic methods for platinum(IV) prodrugs and an understanding of their hydrolytic stability and intracellular activation processes are critical for the development of platinum(IV) prodrugs for cancer therapy. In this review, we summarize recent progress in this field from a comprehensive viewpoint, with an emphasis first on the oxidation processes in chemical environments where platinum(II) compounds are converted to their platinum(IV) species, followed by the reduction processes in biological environments where platinum(IV) species are converted back to platinum(II) forms. First, recent approaches that use new oxidizing reagents to synthesize platinum(IV) prodrugs are summarized, and the oxidation mechanisms and outer-sphere functionalization of platinum(IV) prodrugs are examined. Second, the hydrolysis of platinum(IV) complexes, which has sometimes been underexplored, is discussed, and the factors associated with the hydrolytic stability of platinum(IV) complexes are reviewed. Last, we focus on the reduction of platinum(IV) prodrugs, from the perspectives of reduction potential, rate of reduction, reducing agents, and reduction products. The need for new strategies to achieve controllable intracellular reduction of platinum(IV) prodrugs is emphasized. This review aims to help researchers to improve their understanding of platinum(IV) anticancer prodrugs and hopefully to generate new ideas, strategies, and applications in the area of metal-based drugs.

 

20210518_2.jpeg


Read more: https://doi.org/10.1016/j.ccr.2021.213991

 

 

background
 
 
 
 
 
 
 
 
玩百家乐官网有何技巧| 大发888赌博违法吗| 营口市| 大发888破解老虎机| 商城县| 网上百家乐官网骗人的| 财神百家乐官网的玩法技巧和规则 | 亚洲皇冠| 百家乐官网压分规律| 在线百家乐官网代理| 百家乐官网电影网| 大发888捕鱼| 百家乐官网真人游戏娱乐网| 最新棋牌游戏| 海尔百家乐官网的玩法技巧和规则| 新葡京娱乐城怎么样| 太阳神百家乐官网的玩法技巧和规则 | 单双和百家乐官网游戏机厂家| 大发888婚庆车队| 百家乐英皇赌场娱乐网规则 | 百家乐棋牌交友| 老虎机批发| 百家乐官网入庄闲概率| 百乐门线上娱乐城| 太阳城申博娱乐城| 百家乐娱乐城足球盘网| 全南县| 金木棉百家乐官网的玩法技巧和规则| 六合彩136| 百家乐网络游戏平台| 网上百家乐官网有哪些玩法| 新葡京百家乐的玩法技巧和规则| 百家乐官网国际娱乐网| 宾利百家乐官网现金网| bet365提款| 威尼斯人娱乐下载平台| 王牌百家乐官网的玩法技巧和规则 | 百家乐官网代理每周返佣| 博狗| 威尼斯人娱乐城--老品牌值得您信赖 | 使用的百家乐官网软件|